Literature DB >> 30411509

Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.

Shiori Kamiya1, Junji Kato1, Takafumi Kamiya1, Toshiharu Yamashita1, Yasuyuki Sumikawa1, Tokimasa Hida1, Kohei Horimoto1, Sayuri Sato1, Hitomi Takahashi1, Masahide Sawada1, Terufumi Kubo2, Toshihiko Torigoe2, Hisashi Uhara1.   

Abstract

AIM: To clarify the relationship between programmed cell death ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and clinicopathological variables.
METHODS: We examined PD-L1 expression in tumor cells (TCs) and tumor infiltrating immune cells (ICs) in 46 cases of cSCC by immunohistochemistry. In each case, we employed two methods-intensity and proportion scores-to evaluate PD-L1 expression in TCs. For the evaluation of PD-L1 expression in ICs, only the proportion score was used. Association between PD-L1 expression and clinicopathological variables was analyzed using Fisher's exact test.
RESULTS: High intensity scores in TCs were observed in 18 of the 46 cases (39.1%) and low intensity scores were observed in 28 cases (60.9%). Applying the proportions, using cut-off values of ≥1% and 50%, positive scores in TCs were observed in 36 (78.3%) and 20 cases (43.5%), respectively. PD-L1-positive ICs were observed in 29 (63%) and seven cases (15.2%), using cut-off values of ≥1% and 10%, respectively. The high intensity scores in TCs correlated with lymph node metastasis (P = 0.008) and female gender (P = 0.017), although positive proportions in TCs or ICs were not significantly related to lymph node metastasis. A multivariate analysis showed that high intensity of PD-L1 expression in TCs was an independent risk factor for lymph node metastasis.
CONCLUSIONS: The results suggested that high intensity of PD-L1 expression in TCs is associated with lymph node metastasis in cSCC.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  PD-L1; cutaneous squamous cell carcinoma; immunohistochemistry

Year:  2018        PMID: 30411509     DOI: 10.1111/ajco.13102

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  6 in total

Review 1.  Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response.

Authors:  J S Hooiveld-Noeken; R S N Fehrmann; E G E de Vries; M Jalving
Journal:  Immunooncol Technol       Date:  2019-11-27

2.  PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.

Authors:  Priyadharsini Nagarajan; Christian El-Hadad; Stephen K Gruschkus; Jing Ning; Courtney W Hudgens; Oded Sagiv; Neil Gross; Michael T Tetzlaff; Bita Esmaeli
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

3.  Expression of Programmed Death-Ligand 1 in Cutaneous Squamous Cell Carcinoma Arising in Sun-Exposed and Nonsun-Exposed Skin.

Authors:  Hiroyuki Goto; Kazunari Sugita; Osamu Yamamoto
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

4.  PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer.

Authors:  Abdul K Siraj; Sandeep Kumar Parvathareddy; Padmanaban Annaiyappanaidu; Nabil Siraj; Maha Al-Rasheed; Ismail A Al-Badawi; Fouad Al-Dayel; Khawla S Al-Kuraya
Journal:  Diagnostics (Basel)       Date:  2021-02-25

Review 5.  Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.

Authors:  Connor J Stonesifer; A Reza Djavid; Joseph M Grimes; Alexandra E Khaleel; Yssra S Soliman; Amanda Maisel-Campbell; Tiffany J Garcia-Saleem; Larisa J Geskin; Richard D Carvajal
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

Review 6.  Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.

Authors:  Stephenie Droll; Xiaomin Bao
Journal:  Cell Physiol Biochem       Date:  2021-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.